News

2021-02-26

TW Patent No. I718533 entitled PREPARATION METHOD OF RIBOCICLIB AND ITS SALT AND CRYSTALLINE FORM THEREOF was granted on Feb 11, 2021.

2020-09-30

US Patent No.US10766900B2 entitled Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof was granted on Sep 8, 2020.

2020-09-16

Formosa Labs and Fresenius Kabi enter into a Registration and Distribution Agreement for a breast cancer chemotherapy injection.

2020-09-01

TW Patent No. I703163 entitled Method for preparing Sugammadex Sodium and crystalline form thereof was granted on Sep 1, 2020.

2020-05-12

US Patent No.US10626110B2 entitled Polymorph of Pazopanib Hydrochloride and preparation process thereof was granted on April 21, 2020.

2020-04-01

A message to our clients and business partners concerning COVID-19

2019-01-23

Great Accomplishment of Formosa Labs’ Investment –EirGenix’s Manufacturing Plant Opened in Zhubei, Taiwan

2018-11-01

Passed 5th PAI for Taltirelin and TS-1(Gimeracil, Oteracil, Tegafur)) by PMDA of Japan.

2018-08-17

DE Patent Nr. 10 2009 013 609 entitled Paricalcitol was granted on January 4, 2018.

2018-07-31

Formosa's customer in mainland China get the 1st Montelukast GQCE approval in Chinese mainland.

2018-07-01

TW Patent No. I628187 entitled Process for preparation of Fondaparinux was granted on July 1, 2018.

2018-02-21

Passed 6th US FDA inspection, a PAI for Sevelamer Carbonate

2018-01-31

The Industrial Development Bureau, Taiwan Ministry of Economic Affairs(MOEA) has announced that "Formosa Laboratories Inc." is recommended as domestic pharmaceutical R & D services provider in Taiwan biotech pharmaceutical industry.

Close